Document is current
Any future updates will be listed below
-
Authors
Isnard, Stéphane
Berini, Carolina A.
Parvathy, Seema Nair
Feng, Hansen
Aiyana, Orthy
Royston, Léna
Mabanga, Tsoarello
Lakatos, Peter L.
Bessissow, Talat
Klein, Marina B.
Lebouché, Bertrand
Costiniuk, Cecilia T.
Routy, Bertrand
Silverman, Michael S.
Routy, Jean-Pierre https://orcid.org/0000-0001-9897-7589
-
Funding
Funding for this research was provided by:
Canadian HIV Trials Network, Canadian Institutes of Health Research (CTN PT038)
Fonds de Recherche du Québec - Santé (Cell Therapy network)
CanCURE 3.0
- License Information
-
More Information
Article History
Received: 17 April 2025
Accepted: 26 November 2025
First Online: 13 December 2025
Declarations
:
: The study protocol (version 2.1, dated 11 November 2024) has been approved by the Research Ethics Board (REB) at McGill University Health Centre. All participants provide written informed consent prior to enrollment. Optional sub-study procedures (colon biopsies) require separate informed consent.
: All study participants consent to publication of the study results in aggregate form. No identifying information will be disclosed.
: JPR has performed contract research and/or served on Advisory Boards for Gilead Sciences, Merck, Abbvie, and ViiV Healthcare. BL is supported by a career award from Quebec’s Ministry of Health for researchers in family medicine. BL has received consultancy fees and/or honoraria from Gilead, Merck, and ViiV, and research funds from Gilead, Merck, and ViiV Healthcare, and support to attend educational conferences from ViiV Healthcare and Gilead. CTC is supported by a Fonds de recherche due Québec-Santé Junior 2 career award. The other authors declare no competing interests. If any future competing interests arise during the course of the study or at the time of publication, they will be disclosed accordingly.
